GSK
Global biopharma company licensing AI foundation models and computational-biology platforms across oncology, liver disease, and fibrosis target discovery.
- Company type
- Global pharmaceutical company
- Headquarters
- London, United Kingdom
- Website
- https://www.gsk.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-01-08 — AI foundation-model license with Noetik (Noetik). Anchor partnership giving GSK a non-exclusive license to Noetik's OCTO-VC virtual-cell AI foundation models for non-small cell lung cancer and colorectal cancer research. GSK paid $50 million upfront plus near-term milestones and undisclosed annual subscription fees. Disclosed: $50M upfront; near-term milestones plus undisclosed annual subscription fees. Source: Business Wire (GSK release) (accessed 2026-07-29)
- 2024-12-10 — Target-discovery collaboration with Relation Therapeutics (Relation Therapeutics). Two-stranded collaboration using Relation's "Lab-in-the-Loop" platform and disease datasets — drawing on human genetics, single-cell multi-omics, assays, and machine learning — to identify new targets for fibrotic diseases and osteoarthritis. GSK paid $45 million upfront (including a $15 million equity investment), with up to $63 million in success-based collaboration payments and up to $200 million in milestone payments per target, plus royalties. Disclosed: $45M upfront (incl. $15M equity); up to $63M collaboration payments; up to $200M milestones per target, plus royalties. Source: Fierce Biotech (accessed 2026-07-29)
- 2024-06-12 — Multi-year data-license agreement with Ochre Bio (Ochre Bio). Licensed Ochre Bio's computational-biology platform and human liver multi-omics datasets to further investigate the drivers of liver disease. The agreement was worth up to $37.5 million combined. Disclosed: Up to $37.5M combined. Source: Business Wire (GSK release) (accessed 2026-07-29)